Microba Life Sciences Ltd - Asset Resilience Ratio

Latest as of December 2025: 11.53%

Microba Life Sciences Ltd (MAP) has an Asset Resilience Ratio of 11.53% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$5.00 Million

≈ $3.54 Million USD Cash + Short-term Investments

Total Assets

AU$43.35 Million

≈ $30.68 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Microba Life Sciences Ltd's Asset Resilience Ratio has changed over time. Check Microba Life Sciences Ltd (MAP) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Microba Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MAP market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$5.00 Million	11.53%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$5.00 Million	11.53%

Asset Resilience Insights

Moderate Liquidity: Microba Life Sciences Ltd has 11.53% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Microba Life Sciences Ltd Industry Peers by Asset Resilience Ratio

Compare Microba Life Sciences Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Thyrocare Technologies Limited NSE:THYROCARE	Diagnostics & Research	20.28%
Shanghai Runda Med Tech Co SHG:603108	Diagnostics & Research	0.42%
Integral Diagnostics Ltd AU:IDX	Diagnostics & Research	0.03%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%
Shanghai Rendu Biotechnology Co. Ltd. A SHG:688193	Diagnostics & Research	70.50%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%
BioPorto CO:BIOPOR	Diagnostics & Research	55.77%
RHYTHM Biosciences Ltd AU:RHY	Diagnostics & Research	2.74%

Annual Asset Resilience Ratio for Microba Life Sciences Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Microba Life Sciences Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	6.02%	AU$2.85 Million ≈ $2.02 Million	AU$47.44 Million ≈ $33.56 Million	-1.60pp
2023-12-31	7.61%	AU$4.42 Million ≈ $3.13 Million	AU$58.04 Million ≈ $41.07 Million	-19.28pp
2022-12-31	26.90%	AU$12.63 Million ≈ $8.94 Million	AU$46.95 Million ≈ $33.22 Million	+25.86pp
2021-12-31	1.04%	AU$408.88K ≈ $289.31K	AU$39.48 Million ≈ $27.93 Million	+0.49pp
2020-12-31	0.54%	AU$100.60K ≈ $71.18K	AU$18.49 Million ≈ $13.08 Million	+0.08pp
2019-12-31	0.46%	AU$49.77K ≈ $35.22K	AU$10.81 Million ≈ $7.65 Million	--
2018-12-31	0.00%	AU$0.00 ≈ $0.00	AU$13.99 Million ≈ $9.90 Million	--

pp = percentage points

About Microba Life Sciences Ltd

AU:MAP Australia Diagnostics & Research

Market Cap

$19.39 Million

AU$27.40 Million AUD

Market Cap Rank

#25189 Global

#1064 in Australia

Share Price

AU$0.05

Change (1 day)

+0.00%

52-Week Range

AU$0.04 - AU$0.10

All Time High

AU$0.44